BlossomHill Therapeutics (BLSM) Targets $125M IPO at $15–$17 a Share

BlossomHill Therapeutics has revised its IPO terms, now aiming to raise $125 million by pricing shares in the $15 to $17 range. The updated terms signal that the company and its underwriters are calibrating the offering to attract enough demand while leaving room for a post-listing pop — a common balancing act when a deal is repriced before it hits the market.

The timing is deliberate. BlossomHill is among a group of biotech companies rushing to complete public offerings ahead of what the industry expects to be a more challenging regulatory environment. When companies cluster their IPOs this way, it can reflect a shared belief that the window for favorable conditions is open now but may not stay that way.

For investors watching the IPO, the revised price range is the number to track. Where the final pricing lands within — or outside — the $15 to $17 band will indicate how strong institutional demand proved to be during the roadshow.